They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

While 2024 was a “challenging” year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months. On November 28 ...

Merck's (NYSE:MRK) recent acquisition of rights to Chinese biotech LaNova Medicines' cancer candidate LM-299 in a deal worth up to $3.3B underscores Big Pharma's appetite for best-in-class assets ...

A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...

But local biotech leaders see signs of change in 2025. Amid tough biotech industry market conditions last year, investors and Big Pharma companies were more likely to make deals with later-stage ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023. Moderna plans to move mRNA-1018 to a Phase 3 trial. Shares of Moderna (MRNA) took off Tuesday ...

Plastic is the most prevalent marine pollutant, and plastic surfaces are the fastest growing habitat in the ocean. Researchers at the University of Hawai'i (UH) at Mānoa have recently discovered ...